Results 81 to 90 of about 3,125,328 (279)

Architecture of an All‐In‐One Microfluidic Platform for Accelerated Cancer Seeding, Enhanced Spheroid Formation, and Dynamic Drug Screening Trials

Advanced Materials Technologies, EarlyView.
An all‐in‐one microfluidic platform consists of two‐layered PDMS channels integrated with a hydrogel microwell array. This platform enables flow‐driven tumor cell capture, enhanced spheroid formation within the microwells, and advective drug testing. ABSTRACT Effective cancer drug screening requires platforms that replicate the physiological complexity
Omar M. Rahman, Shengxi Lan, Dae Kun Hwang   +2 more
wiley   +1 more source

The interaction between UBR7 and PRMT5 drives PDAC resistance to gemcitabine by regulating glycolysis and immune microenvironment

Cell Death and Disease
Pancreatic ductal adenocarcinoma (PDAC) is a common malignant tumor of the digestive tract. Although gemcitabine and other therapeutic agents are effective in patients with advanced and metastatic pancreatic cancer, drug resistance has severely limited ...
Maoxiao Feng, Qinlian Jiao, Yidan Ren, Xiaoyan Liu, Zihan Gao, Zhengjun Li, Yunshan Wang, Miaoqing Zhao, Lei Bi   +8 more
doaj   +1 more source

Elevated PAF1-RAD52 axis confers chemoresistance to human cancers

Cell Reports, 2023
Summary: Cisplatin- and gemcitabine-based chemotherapeutics represent a mainstay of cancer therapy for most solid tumors; however, resistance limits their curative potential.
Sanchita Rauth, Koelina Ganguly, Pranita Atri, Seema Parte, Rama Krishna Nimmakayala, Venkatesh Varadharaj, Palanisamy Nallasamy, Raghupathy Vengoji, Ayoola O. Ogunleye, Imayavaramban Lakshmanan, Ramakanth Chirravuri, Mika Bessho, Jesse L. Cox, Jason M. Foster, Geoffrey A. Talmon, Tadayoshi Bessho, Apar Kishor Ganti, Surinder K. Batra, Moorthy P. Ponnusamy   +18 more
doaj   +1 more source

Interferon‐Driven Biomarkers and Synergistic Therapy for PRMT5 Inhibition in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
Triple‐negative breast cancer exhibits variable sensitivity to PRMT5 inhibition. Basal interferon signaling is identified as a key biomarker of response. PARP inhibition with olaparib induces IFN signaling, sensitizing resistant TNBC cells to PRMT5 inhibitors.
Ziwen Zhang, Sheyu Zhang, Lu Guo, Yichun Pan, Juan Huang, Yishuai Ji, Jiaqi Tao, Yong Wei, Xiaojia Wang, Qin Wu   +9 more
wiley   +1 more source

MiR-9-3p regulates the biological functions and drug resistance of gemcitabine-treated breast cancer cells and affects tumor growth through targeting MTDH [PDF]

, 2021
Yike Wang, Lifeng Dong, Fangping Wan, Fangfang Chen, Dianlei Liu, Deqin Chen, Jingpei Long   +6 more
openalex   +1 more source

Interactions of Antibody Drug Conjugate Anti‐Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy

Advanced Science, EarlyView.
Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.
Jacqueline Lesperance, Bryan S. Yung, Michael M. Allevato, Marcus M Cheng, Maria F. Camargo, Robert Saddawi‐Konefka, Kanika Dhawan, Ashwyn K. Sharma, Mahsa Mortaja, Sophie Bice, Daniel J. Scanderbeg, Diego Alvarado, Jyoti Mayadev, Ramez N. Eskander, Stephen R. Adams, Pippa F. Cosper, J. Silvio Gutkind, Sunil J. Advani   +17 more
wiley   +1 more source

Increased m6A modification of lncRNA DBH-AS1 suppresses pancreatic cancer growth and gemcitabine resistance via the miR-3163/USP44 axis

Annals of Translational Medicine, 2022
Background Gemcitabine is among the most commonly utilized chemotherapeutic agents for treating pancreatic cancer (PC), yet patients ultimately develop chemoresistance and thus exhibit a poor prognosis.
Xin Ye, Li-ping Wang, Cong Han, Hao-Huan Hu, Chen-ming Ni, Guang Qiao, Ou-Fei Liu, Jun-sheng Ni   +7 more
semanticscholar   +1 more source

Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione‐Mediated Stemness Maintenance

Advanced Science, EarlyView.
PDAC has a poor prognosis due to chemoresistance. We revealed that MCU upregulation is associated with chemoresistance and stemness in PDAC. MCU‐mediated Ca2+ influx induced ER stress, activating the PERK‐ATF4/NRF2 axis to enhance PSAT1/SLC711 expression and glutathione synthesis, reducing ROS and maintaining stemness.
Zekun Li, Chenyang Meng, Guangcong Shen, Yueying Shan, Junjin Wang, Diliyaer Abudukeremu, Rui Zhao, Bo Ni, Chao Xu, Xiaofan Guo, Jun Yu, Kaiyuan Wang, Shengyu Yang, YunZhan Li, Yongjie Xie, Tianxing Zhou, Jihui Hao, Xiuchao Wang   +17 more
wiley   +1 more source

mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer

Neoplasia: An International Journal for Oncology Research, 2021
Ribonucleotide reductase (RNR) is the key enzyme that catalyzes the production of deoxyribonucleotides (dNTPs) for DNA replication and it is also essential for cancer cell proliferation.
Ling Tian, Congcong Chen, Yanguan Guo, Fan Zhang, Jinye Mi, Qi Feng, Shengbin Lin, Naite Xi, Jiaxin Tian, Li Yu, Yan Chen, Mingrong Cao, Caiyong Lai, Jun Fan, Yongchang Zhang, Guo Chen   +15 more
doaj   +1 more source

Positive Feedback Loop of Histone Lactylation‐Driven HNRNPC Promotes Autophagy to Confer Pancreatic Ductal Adenocarcinoma Gemcitabine Resistance

Advanced Science, EarlyView.
Histone 3 lysine18 lactylation (H3K18la) drives heterogeneous nuclear ribonucleoprotein C (HNRNPC) overexpression, activating autophagy to mediate gemcitabine resistance by stabilizing TNF receptor‐associated factor 6 (TRAF6) mRNA. Concurrently, HNRNPC stabilizes aldehyde dehydrogenase 1 family member A3 (ALDH1A3) mRNA, which enhances glycolysis and ...
Xi‐Tai Huang, Jiao Chen, En‐Liang Zhu, Ming‐Jian Ma, Yang‐Yin‐Hui Yu, Ying‐Qin Zhu, Jing‐Yuan Ye, Jin‐Zhao Xie, Zi‐Yi Zhao, Xiao‐Yu Yin   +9 more
wiley   +1 more source